Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE HYDROCHLORIDE versus LORAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE HYDROCHLORIDE versus LORAZ.
CHLORDIAZEPOXIDE HYDROCHLORIDE vs LORAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptor, enhancing GABA-mediated chloride ion influx, leading to neuronal hyperpolarization and reduced excitability.
Binds to gamma-aminobutyric acid (GABA) type A receptors at the benzodiazepine binding site, potentiating the effect of GABA, leading to increased chloride ion influx, neuronal hyperpolarization, and inhibition of neurotransmission.
Oral: 5-25 mg 3-4 times daily, up to 100 mg/day in severe anxiety; IM/IV: 50-100 mg initially, then 25-50 mg 3-4 times daily.
2-6 mg orally or intravenously daily in divided doses; usual range 2-10 mg/day
None Documented
None Documented
Terminal elimination half-life: 6.6 to 28 hours (parent drug); clinically, duration of effect may be prolonged due to active metabolite nordazepam (half-life 30-100 hours), especially in elderly or hepatic impairment.
Clinical Note
moderateClorazepic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."
Clinical Note
moderateTerminal elimination half-life: 12–15 hours in healthy adults. Extended in elderly (15–20 hours), hepatic impairment (up to 50 hours), and obesity.
Renal: approximately 50-60% as metabolites (mainly conjugated forms), with less than 1% unchanged. Fecal: minor, about 10%. Biliary excretion contributes to enterohepatic circulation.
Renal: ~85% as glucuronide conjugates and ~10% as unchanged drug. Biliary/fecal: ~5%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
Lorazepam + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Lorazepam."